|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Urologic Diseases
|
NCI
|
5R13CA121807-02
|
|
CSHL Conference on PTEN Pathways
|
STEWART, DAVID
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$7,000
|
|
Urologic Diseases
|
NCI
|
1R01CA116379-01A1
|
|
3-D Transrectal Ultrasound with 2-D Arrays
|
YEN, JESSE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$248,168
|
|
Urologic Diseases
|
NCI
|
5R01CA104922-04
|
|
Phenolic antioxidants as tumor radio/chemosensitizers
|
KOUMENIS, CONSTANTINOS
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$261,121
|
|
Urologic Diseases
|
NCI
|
4R37CA058596-16
|
|
Functional Properties of the Wilms' Tumor Gene WT1
|
HABER, DANIEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$436,192
|
|
Urologic Diseases
|
NIAID
|
5R01AI062755-04
|
|
Sexually Transmitted Infections & Antimicrobial Peptides
|
SHAFER, WILLIAM
|
EMORY UNIVERSITY
|
GA
|
$318,814
|
|
Urologic Diseases
|
NCI
|
5R01CA112310-04
|
|
Role of Raf Kinase Inhibitory Protein in Prostate Cancer
|
ROSNER, MARSHA
|
UNIVERSITY OF CHICAGO
|
IL
|
$297,116
|
|
Urologic Diseases
|
NIAID
|
5R01AI059650-05
|
|
Host response to Chlamydia genital infection in the male
|
RANK, ROGER
|
ARKANSAS CHILDREN'S HOSPITAL RES INST
|
AR
|
$332,534
|
|
Urologic Diseases
|
NCI
|
7K99CA125937-02
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$89,179
|
|
Urologic Diseases
|
NIEHS
|
5F32ES014284-03
|
|
TCDD Impairs Prostate Development: Cyp2c39 & Retinoids
|
VEZINA, CHAD
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$52,048
|
|
Urologic Diseases
|
NIAID
|
5R01AI059523-04
|
|
Orgin of multidrug resistant uropathogenic E. coli
|
RILEY, LEE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$282,770
|
|
Urologic Diseases
|
NIA
|
2R44AG015259-04
|
|
Novel Drugs to Treat Urinary Incontinence
|
CHEN, JAN
|
GLSYNTHESIS, INC.
|
MA
|
$794,658
|
|
Urologic Diseases
|
NICHD
|
5R01HD046861-04
|
|
Unveil a Novel Pathway in Mammalian Ovary Development
|
YAO, HUMPHREY
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
IL
|
$312,716
|
|
Urologic Diseases
|
NIDDK
|
5R37DK047556-14
|
|
HEPARIN-BINDING EGF-LIKE FACTORS IN PROSTATE GROWTH
|
FREEMAN, MICHAEL
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$361,146
|
|
Urologic Diseases
|
NCI
|
5F31CA113285-04
|
|
Mechanism of ART-27 Function in Prostate Cancer
|
NWACHKWU, JEROME
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$46,864
|
|
Urologic Diseases
|
NCI
|
5F31CA113268-03
|
|
HTS for Small Molecule Inhibitors of the RhoA Pathway
|
EVELYN, CHRIS
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$32,641
|
|
Urologic Diseases
|
NIAID
|
5R01AI042015-10
|
|
Regulation of the (poly) sialic virulence factor
|
VIMR, ERIC
|
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
|
IL
|
$177,895
|
|
Urologic Diseases
|
NIDDK
|
5R37DK051193-13
|
|
Role of U19/Eaf2 in androgen-dependent prostate homeostasis
|
WANG, ZHOU
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$289,685
|
|
Urologic Diseases
|
NIAID
|
5R01AI031940-18
|
|
Genetic Analysis of Cholera Toxin Structure and Function
|
HOLMES, RANDALL
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$562,026
|
|
Urologic Diseases
|
NICHD
|
5U01HD045908-05
|
|
Junction Dynamics and Male Fertility Regulation
|
CHENG, C.
|
POPULATION COUNCIL
|
NY
|
$193,233
|
|
Urologic Diseases
|
NIAID
|
5R01AI048689-08
|
|
Pathogenic Fiber Formation in Bacteria: Structural Basis
|
HULTGREN, SCOTT
|
WASHINGTON UNIVERSITY
|
MO
|
$361,970
|
|
Urologic Diseases
|
NCI
|
5R01CA111868-04
|
|
Interactions and Functions of p14ARF in Cancer
|
GJERSET, RUTH
|
SIDNEY KIMMEL CANCER CENTER
|
CA
|
$370,484
|
|
Urologic Diseases
|
NCI
|
5R37CA034992-26
|
|
CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGS
|
LIPPARD, STEPHEN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$672,247
|
|
Urologic Diseases
|
NIDDK
|
5R37DK045370-11
|
|
Prevention and Treatment of Impotence
|
LUE, TOM
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$330,824
|
|
Urologic Diseases
|
NCI
|
5R33CA118591-03
|
|
An RNA Sensor for Detection of Circulating Tumor Cells
|
CLAWSON, GARY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$284,503
|
|
Urologic Diseases
|
NCI
|
5F32CA112988-03
|
|
Deciphering Beta-Catenin Contributions in Prostate Cance
|
MULHOLLAND, DAVID
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$48,796
|
|
Urologic Diseases
|
NCI
|
5R01CA120451-02
|
|
Pomegranate for Chemoprevention and Chemotherapy of Prostate Cancer
|
MUKHTAR, HASAN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$279,300
|
|
Urologic Diseases
|
NCI
|
5R01CA102751-04
|
|
MR Based Molecular Imaging of Prostate Cancer
|
KURHANEWICZ, JOHN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$252,330
|
|
Urologic Diseases
|
NICHD
|
5K23HD045769-05
|
|
Vulvar Disease and Bladder and Bowel Symptoms
|
KENNEDY, COLLEEN
|
UNIVERSITY OF IOWA
|
IA
|
$114,505
|
|
Urologic Diseases
|
NICHD
|
5R01HD044258-05
|
|
Intratesticular Testosterone and Spermatogenesis in Man
|
ZIRKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$433,347
|
|
Urologic Diseases
|
NCI
|
5R33CA110518-03
|
|
PSA BASED EARLY DETECTION OF PROSTATE CANCER RECURRENCE
|
TAYLOR, JEREMY
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$319,472
|
|
Urologic Diseases
|
NIDDK
|
5K08DK069608-04
|
|
Molecular Basis of Bladder Organogenesis
|
REDDY, PRAMOD
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$126,010
|
|
Urologic Diseases
|
NCI
|
5R01CA116673-02
|
|
Clinical Trial of Selenium and Prostate Biomarkers
|
MARSHALL, JAMES
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$410,787
|
|
Urologic Diseases
|
NCI
|
5R01CA075284-09
|
|
Improved Cryosurgical Destruction of Prostate Cancer
|
BISCHOF, JOHN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$319,374
|
|
Urologic Diseases
|
NIDDK
|
5R01DK073402-03
|
|
Role of FKBP52 in androgen signaling and hypospadias
|
SHOU, WEINIAN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$255,352
|
|
Urologic Diseases
|
NCI
|
5R01CA109460-03
|
|
PI3K Pathway in Prostate Tumorigenesis and Angiogenesis
|
JIANG, BING-HUA
|
WEST VIRGINIA UNIVERSITY
|
WV
|
$227,246
|
|
Urologic Diseases
|
NCI
|
5R01CA103943-05
|
|
Role of RNase L in the Biology of Prostate Cancer
|
SILVERMAN, ROBERT
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$297,398
|
|
Urologic Diseases
|
NIDDK
|
5R01DK057267-06
|
|
Afferent plasticity underlying urethral and pelvic pain
|
YOSHIMURA, NAOKI
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$259,771
|
|
Urologic Diseases
|
NCI
|
7R01CA104334-05
|
|
PREVENTION OF PROSTATIC CARCINOGENESIS BY ANTIOXIDANTS
|
BOSLAND, MAARTEN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$244,138
|
|
Urologic Diseases
|
NCI
|
5R01CA109147-03
|
|
AR and RUNX2 target genes in prostate cancer
|
COETZEE, GERHARD
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$252,841
|
|
Urologic Diseases
|
NCI
|
5R01CA105125-04
|
|
Ceramide synthase as a therapy target in prostate cancer
|
HAIMOVITZ-FRIEDMAN, ADRIANA
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$319,439
|
|
Urologic Diseases
|
NIDDK
|
5R01DK069690-03
|
|
Development of a Urological CD Cell Typing System
|
NELSON, PETER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$326,252
|
|
Urologic Diseases
|
NCI
|
5R21CA118362-02
|
|
Targeting Relaxin Signaling in Prostate Cancer
|
AGOULNIK, ALEXANDER
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$150,000
|
|
Urologic Diseases
|
NIDDK
|
5R03DK076556-02
|
|
Targeting the E. coli chaperone SurA in recurrent UTI
|
HUNSTAD, DAVID
|
WASHINGTON UNIVERSITY
|
MO
|
$74,480
|
|
Urologic Diseases
|
NCI
|
5R01CA116242-02
|
|
Tea Polyphenols in Chemoprevention of Prostate Cancer
|
HENNING, SUSANNE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$264,195
|
|
Urologic Diseases
|
NCI
|
5R01CA119334-29
|
|
Technetium and Rhenium in Nuclear Medicine
|
JONES, ALUN
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$563,873
|
|
Urologic Diseases
|
NIGMS
|
5R01GM064559-07
|
|
Heterocumulenes in Asymmetric Catalysis
|
LECTKA, THOMAS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$261,467
|
|
Urologic Diseases
|
NCI
|
5R01CA106826-04
|
|
Developmental Transcription Factors in Prostate Cancer
|
MORENO, CARLOS
|
EMORY UNIVERSITY
|
GA
|
$229,214
|
|
Urologic Diseases
|
NICHD
|
5U01HD045913-05
|
|
A Novel Gene Required for Sertoli-Spermatids Adhesion
|
MACGREGOR, GRANT
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$293,251
|
|
Urologic Diseases
|
NIDDK
|
5R01DK074741-02
|
|
Prevention of Kidney Stone Crystal Retention
|
KLEINMAN, JACK
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$222,597
|
|
Urologic Diseases
|
NIDDK
|
1SC2DK082388-01
|
|
Regeneration of the Pelvic and Urethral Supports by Muscle Derived Stem Cells
|
HO, MATTHEW
|
CHARLES R. DREW UNIVERSITY OF MED & SCI
|
CA
|
$141,125
|
|
Urologic Diseases
|
FIC
|
1R03TW007754-01A1
|
|
Pathogenesis of persistent C. trachomatis STDs
|
DEAN, DEBORAH
|
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
|
CA
|
$39,728
|
|
Urologic Diseases
|
NHLBI
|
5R01HL026043-27
|
|
Myosin Light Chain Kinase Function in Smooth Muscle
|
STULL, JAMES
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$369,790
|
|
Urologic Diseases
|
NIDDK
|
5U01DK056943-08
|
|
Kansas Polycystic Kidney Imaging Program (CRISPII)
|
GRANTHAM, JARED
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$320,568
|
|
Urologic Diseases
|
NIDDK
|
5U01DK056957-08
|
|
Polycystic Kidney Disease: Innovative Imaging to Assess Progression (PCC)
|
TORRES, VICENTE
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$369,513
|
|
Urologic Diseases
|
NIDDK
|
5U01DK056956-08
|
|
"The Early Collaborative Clinical Studies in PKD: The C*
|
CHAPMAN, ARLENE
|
EMORY UNIVERSITY
|
GA
|
$337,438
|
|
Urologic Diseases
|
NIDDK
|
5U01DK056961-09
|
|
Data Coordinating and Image Analysis for CRISP-II
|
BAE, KYONGTAE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$428,981
|
|
Urologic Diseases
|
NICHD
|
5R01HD044569-04
|
|
FSH and Retinoid Signaling in the Testis
|
KIM, KWAN
|
WASHINGTON STATE UNIVERSITY
|
WA
|
$273,184
|
|
Urologic Diseases
|
NCI
|
5R01CA102537-05
|
|
Role of Cten in Prostate Cancer
|
LO, SU
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$221,769
|
|
Urologic Diseases
|
NINDS
|
5R01NS050514-04
|
|
Neural Prosthetic Control of Continence and Micturition
|
GRILL, WARREN
|
DUKE UNIVERSITY
|
NC
|
$427,362
|
|
Urologic Diseases
|
NCI
|
7R01CA109441-04
|
|
IL-4 and androgen receptor signaling in prostate cancer
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$213,141
|
|
Urologic Diseases
|
NCI
|
5R01CA111846-03
|
|
Prx1 in malignant progression of prostate cancer
|
PARK, YOUNG-MEE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$307,083
|
|
Urologic Diseases
|
NIAID
|
5R01AI059722-04
|
|
Reciprocal Control of Motility and Adherence in UTI
|
MOBLEY, HARRY
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$348,946
|
|
Urologic Diseases
|
NCI
|
5R01CA112028-04
|
|
Cell Cycle Variants and Metastatic Prostate Cancer Risk
|
KIBEL, ADAM
|
WASHINGTON UNIVERSITY
|
MO
|
$229,214
|
|
Urologic Diseases
|
NCI
|
5R21CA114547-02
|
|
Intervention to Enhance Quality of Life in Men with PCa: Development and Testing
|
ELLER, LUCILLE
|
RUTGERS THE STATE UNIV OF NJ NEWARK
|
NJ
|
$154,500
|
|
Urologic Diseases
|
NCI
|
5R01CA111421-04
|
|
Apoptosis by FADD in normal and cancerous cells
|
THORBURN, ANDREW
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$288,389
|
|
Urologic Diseases
|
NCI
|
5R01CA105402-05
|
|
Androgen and Growth Factor Signaling in Prostate Cancer
|
WEBER, MICHAEL
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$148,210
|
|
Urologic Diseases
|
NIDDK
|
5R01DK073732-03
|
|
Endogenous Oxalate Synthesis
|
HOLMES, ROSS
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$279,931
|
|
Urologic Diseases
|
NIDDK
|
5R01DK056245-09
|
|
Oxalate Handling in PAT1 and DRA Knockout Mice
|
HATCH, MARGUERITE
|
UNIVERSITY OF FLORIDA
|
FL
|
$291,706
|
|
Urologic Diseases
|
NCI
|
5R01CA111891-03
|
|
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
|
LU, QUN
|
EAST CAROLINA UNIVERSITY
|
NC
|
$184,029
|
|
Urologic Diseases
|
NCI
|
5R01CA102074-05
|
|
Androgen Control of TGF-beta signaling
|
DANIELPOUR, DAVID
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$293,511
|
|
Urologic Diseases
|
NCI
|
5R01CA107166-05
|
|
PTEN and Prostate Cancer Progression
|
WU, HONG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$297,832
|
|
Urologic Diseases
|
NIDDK
|
5R01DK051413-11
|
|
Quantitative studies of urinary bladder sensation
|
NESS, TIMOTHY
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$291,305
|
|
Urologic Diseases
|
NIDDK
|
5R01DK069898-04
|
|
Disruption of Caldesmon Gene Expression in Bladder Myocytes
|
CHACKO, SAMUEL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$349,802
|
|
Urologic Diseases
|
NIDDK
|
5R01DK072277-02
|
|
In Vivo Ca2+ and Voltage Imaging on The Urinary Bladder
|
KOTLIKOFF, MICHAEL
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$312,679
|
|
Urologic Diseases
|
NIAID
|
5R01AI046613-09
|
|
Innate Immune Receptors in Host Responses to Neisseria
|
INGALLS, ROBIN
|
BOSTON MEDICAL CENTER
|
MA
|
$311,747
|
|
Urologic Diseases
|
NIDDK
|
5R01DK068474-03
|
|
Role of Tamm-Horsfall Protein in Urinary Track Infection
|
KUMAR, SATISH
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$285,783
|
|
Urologic Diseases
|
NCI
|
5R01CA107039-04
|
|
Rexinoid Synergy in Prostate Cancer Apoptosis
|
DAWSON, MARCIA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$510,361
|
|
Urologic Diseases
|
NCI
|
5R01CA114060-03
|
|
SELECT Pre-Clinical Trial of Prostate Cancer
|
AHMAD, NIHAL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$250,774
|
|
Urologic Diseases
|
NIBIB
|
5R21EB005331-02
|
|
Human Copper Transporter 1 as Reporter Gene for Imaging
|
PENG, FANGYU
|
WAYNE STATE UNIVERSITY
|
MI
|
$184,363
|
|
Urologic Diseases
|
NCI
|
5R01CA112303-04
|
|
Membrane Microdomains in Prostate Cancer
|
FREEMAN, MICHAEL
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$284,832
|
|
Urologic Diseases
|
NCI
|
5R01CA098513-05
|
|
Prostate Cancer Metastasis Suppressor: Role of RKIP
|
KELLER, EVAN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$237,918
|
|
Urologic Diseases
|
NIAID
|
5F32AI068324-02
|
|
Genomic Approach to Vaccine Design for Proteus mirabilis
|
PEARSON, MELANIE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$51,278
|
|
Urologic Diseases
|
NCI
|
5R01CA058093-15
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$256,863
|
|
Urologic Diseases
|
NICHD
|
5R01HD046743-05
|
|
Steroidogenic Factor 1: Mediator of Gonadal Function
|
PARKER, KEITH
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$293,541
|
|
Urologic Diseases
|
NCI
|
5R01CA104035-04
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$280,899
|
|
Urologic Diseases
|
NCI
|
1R01CA131013-01
|
|
Multi-parametric MRI Determination of Prostate Cancer Aggressiveness and Extent
|
METZGER, GREGORY
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$311,293
|
|
Urologic Diseases
|
NICHD
|
5R01HD030284-15
|
|
Molecular Genetics of Female Reproductive Tract
|
BEHRINGER, RICHARD
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$315,702
|
|
Urologic Diseases
|
NIAID
|
5R01AI059440-05
|
|
Understanding the role of a novel Toll-like receptor
|
GHOSH, SANKAR
|
YALE UNIVERSITY
|
CT
|
$380,205
|
|
Urologic Diseases
|
NCI
|
1R01CA131226-01
|
|
Efficacy and Mechanism of Novel Androgen Receptor Inhibitors
|
DIAMOND, MARC
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$320,241
|
|
Urologic Diseases
|
NICHD
|
1R01HD057501-01
|
|
The Mechanism of Cryptorchidism in LH Receptor Knockout Animals
|
LEI, ZHENMIN
|
UNIVERSITY OF LOUISVILLE
|
KY
|
$293,047
|
|
Urologic Diseases
|
NCI
|
5R01CA096991-05
|
|
Molecular Mechanism of KAI1/CD82-mediated Suppression
|
ZHANG, XIN
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$218,035
|
|
Urologic Diseases
|
NINDS
|
5R01NS039358-09
|
|
Specificity of RET signaling: physiology and regulation
|
MILBRANDT, JEFFREY
|
WASHINGTON UNIVERSITY
|
MO
|
$335,479
|
|
Urologic Diseases
|
NCI
|
5R01CA120368-02
|
|
Micro CT/NIR Molecular Imaging of Cancer
|
POGUE, BRIAN
|
DARTMOUTH COLLEGE
|
NH
|
$237,718
|
|
Urologic Diseases
|
NINDS
|
5R01NS035790-11
|
|
Peripheral Contributions to Bladder Hypersensitivity
|
GEBHART, GERALD
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$415,819
|
|
Urologic Diseases
|
NIDDK
|
5K01DK070909-03
|
|
Beta-adrenergic relaxation of urinary bladder smooth muscle
|
PETKOV, GEORGI
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
SC
|
$135,552
|
|
Urologic Diseases
|
NCI
|
5R01CA060651-16
|
|
Mouse Models to Study Gonadal Tumor Development
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$265,968
|
|
Urologic Diseases
|
NCI
|
5R01CA064851-14
|
|
KGF in Prostate Cancer: A Transgenic Animal Model
|
GREENBERG, NORMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$336,274
|
|
Urologic Diseases
|
NIDDK
|
5R37DK033793-25
|
|
Roles of SLC26A6 in Renal NaCI Transport and Prevention of Oxalate Urolithiasis
|
ARONSON, PETER
|
YALE UNIVERSITY
|
CT
|
$544,412
|
|
Urologic Diseases
|
NCI
|
5R21CA122693-02
|
|
PET-guided Intervention in Lymphatic Metastasis of Prostate Cancer
|
WU, LILY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$185,400
|
|
Urologic Diseases
|
NCI
|
1R21CA131603-01
|
|
A New Class of Mechanistic Risk Prediction Models for Cancer Treatment Outcomes
|
HUANG, LI-SHAN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$170,820
|
|
Urologic Diseases
|
NCI
|
5R01CA102688-05
|
|
Validation of a New Target for Prostate Cancer Therapy
|
BARON, VERONIQUE
|
SIDNEY KIMMEL CANCER CENTER
|
CA
|
$289,700
|
|
Urologic Diseases
|
NCI
|
5R01CA095739-08
|
|
Store-Operated Calcium Entry and Apoptosis
|
MA, JIANJIE
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$245,631
|
|
Urologic Diseases
|
NCI
|
1R21CA131754-01
|
|
Decision Making in Patients with Advanced Prostate Cancer
|
JONES, RANDY
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$229,141
|
|
Urologic Diseases
|
NCI
|
5R01CA097543-04
|
|
Metabolism of Vitamin A in the Prostate
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$251,685
|
|
Urologic Diseases
|
NINDS
|
5R01NS042719-05
|
|
Repair of Bladder Function after Cauda Equina Injury
|
HAVTON, LEIF
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$337,969
|
|
Urologic Diseases
|
NCI
|
1R21CA131774-01
|
|
Small RNA targeted gene activation for the treatment of prostate cancer
|
LI, LONG-CHENG
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$208,238
|
|
Urologic Diseases
|
NCI
|
5R01CA046283-20
|
|
MECHANISMS OF EPITHELIAL CELL TUMORIGENESIS IN THE MOUSE
|
VAN DYKE, TERRY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$479,600
|
|
Urologic Diseases
|
NCI
|
5R01CA105304-05
|
|
Genomic and proteomic analysis of prostate cancer
|
SADAR, MARIANNE
|
BRITISH COLUMBIA CANCER AGENCY
|
CANADA
|
$209,928
|
|
Urologic Diseases
|
NCI
|
7R01CA118887-03
|
|
Selenium regulates androgen receptor signaling in prostate cancer
|
GAO, ALLEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$235,778
|
|
Urologic Diseases
|
NCI
|
5U10CA058882-16
|
|
Southwest Oncology Group
|
LENZ, HEINZ
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$256,651
|
|
Urologic Diseases
|
NIDDK
|
1R01DK075462-01A2
|
|
Contribution of increased VDR and CaR to Hypercalciuria in the GHS Rat
|
BUSHINSKY, DAVID
|
UNIVERSITY OF ROCHESTER
|
NY
|
$307,855
|
|
Urologic Diseases
|
NCI
|
1R21CA132033-01
|
|
Targeted polymeric nanocarriers for combination therapy of prostate cancer
|
FORREST, MARCUS
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$164,470
|
|
Urologic Diseases
|
NCI
|
5R01CA116636-03
|
|
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$261,397
|
|
Urologic Diseases
|
NCI
|
5R21CA121782-02
|
|
Cell-targeting peptide nucleic acids for hormone-refractory prostate cancer
|
BARTON, BEVERLY
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
NJ
|
$187,200
|
|
Urologic Diseases
|
NIA
|
5R44AG029029-03
|
|
Software for Meta-Analysis of Diagnostic Tests
|
BORENSTEIN, MICHAEL
|
BIOSTATISTICAL PROGRAMMING ASSOC, INC.
|
NJ
|
$474,666
|
|
Urologic Diseases
|
NCI
|
5U10CA105409-05
|
|
U10 Ful Member Application Affiliated with SWOG
|
LIPPMAN, SCOTT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$71,573
|
|
Urologic Diseases
|
NCI
|
5R37CA081301-10
|
|
Metabolism of Carcinogenic Tobacco-Specific Nitrosamines
|
HECHT, STEPHEN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$477,962
|
|
Urologic Diseases
|
NIGMS
|
1R15GM083261-01
|
|
Synthesis of Various C-Linked Glycopeptides of Biomedical Interest
|
NOLEN, ERNEST
|
COLGATE UNIVERSITY
|
NY
|
$206,810
|
|
Urologic Diseases
|
NCI
|
5R01CA103934-03
|
|
MR Diffusion Tensor Imaging of Prostate Cancer
|
VIGNERON, DANIEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$261,115
|
|
Urologic Diseases
|
NCI
|
5R01CA104286-05
|
|
Pure Flavonolignans from S. marianum in Prostate Cancer
|
KROLL, DAVID
|
RESEARCH TRIANGLE INSTITUTE
|
NC
|
$386,258
|
|
Urologic Diseases
|
NCI
|
5R01CA111618-04
|
|
Protocadherin-PC and Prostate Cancer
|
BUTTYAN, RALPH
|
ORDWAY RESEARCH INSTITUTE, INC.
|
NY
|
$275,333
|
|
Urologic Diseases
|
NCI
|
5R01CA109874-04
|
|
Beta1 Integrins and IGF-I Receptor in Prostate Cancer
|
LANGUINO, LUCIA
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$273,876
|
|
Urologic Diseases
|
NCI
|
5R01CA114469-05
|
|
Mechanisms of Chemoprevention by Resveratrol
|
SRIVASTAVA, RAKESH
|
UNIVERSITY OF TEXAS HLTH CTR AT TYLER
|
TX
|
$168,184
|
|
Urologic Diseases
|
NICHD
|
5R01HD054554-02
|
|
Cell Signaling and Lineage During Penile Development
|
COHN, MARTIN
|
UNIVERSITY OF FLORIDA
|
FL
|
$300,367
|
|
Urologic Diseases
|
NCI
|
7R01CA115717-02
|
|
Modeling androgen-independent prostate cancer in mutant mice
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$305,900
|
|
Urologic Diseases
|
NCI
|
5R01CA102218-05
|
|
TRAIL-induced apoptosis in prostate cancer
|
VOELKEL-JOHNSON, CHRISTINA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$249,182
|
|
Urologic Diseases
|
NIA
|
5R03AG028057-02
|
|
Clinical Features in Nursing Home Residents with Suspected UTI
|
JUTHANI-MEHTA, MANISHA
|
YALE UNIVERSITY
|
CT
|
$66,431
|
|
Urologic Diseases
|
NIAID
|
5R21AI064444-02
|
|
Archaeal gene recruitment by the Chlamydiales
|
GRAHAM, DAVID
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$182,084
|
|
Urologic Diseases
|
NIDDK
|
1R01DK077950-01A1
|
|
Genetic determinants of urine lithogenicity
|
LIESKE, JOHN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$344,440
|
|
Urologic Diseases
|
NIA
|
7R01AG024278-03
|
|
Genetic Analysis of a Prostate Tumor Suppressor Region
|
MARKER, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$289,683
|
|
Urologic Diseases
|
NCCAM
|
5R21AT002743-02
|
|
Role of iron homeostasis in cranberry's bio-effects
|
GUO, MAOLIN
|
UNIVERSITY OF MASSACHUSETTS DARTMOUTH
|
MA
|
$180,460
|
|
Urologic Diseases
|
NIAID
|
5R01AI072728-02
|
|
Ureaplasmas in acute and persistent urethritis: clinical implications
|
MANHART, LISA
|
UNIVERSITY OF WASHINGTON
|
WA
|
$376,399
|
|
Urologic Diseases
|
NCI
|
5R01CA120386-02
|
|
Role of Eaf family proteins in prostate carcinogenesis
|
WANG, ZHOU
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$282,150
|
|
Urologic Diseases
|
NCI
|
2R01CA058073-15A1
|
|
Molecular Mechanisms of Growth Control in Prostate Cancer
|
LIAO, SHUTSUNG
|
UNIVERSITY OF CHICAGO
|
IL
|
$315,168
|
|
Urologic Diseases
|
NIDDK
|
1R01DK077777-01A1
|
|
Adenosine Receptor Function in Bladder Uroepithelium
|
APODACA, GERARD
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$407,089
|
|
Urologic Diseases
|
NIAID
|
5R01AI045820-08
|
|
Pathogenic Adaptation of Microbial Adhesins
|
SOKURENKO, EVGENI
|
UNIVERSITY OF WASHINGTON
|
WA
|
$297,196
|
|
Urologic Diseases
|
NIDDK
|
1R01DK078045-01A1
|
|
Risk factors for renal scarring in children after urinary tract infection
|
KEREN, RON
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$623,398
|
|
Urologic Diseases
|
NIA
|
2R01AG020629-06
|
|
Further Enhancing Non-Pharmacological Therapy for Incontinence
|
RESNICK, NEIL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$461,336
|
|
Urologic Diseases
|
NCI
|
2R01CA085567-06A2
|
|
The Role of CDK5 in Metastasis
|
NELKIN, BARRY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$350,509
|
|
Urologic Diseases
|
NCI
|
2R01CA089406-07A2
|
|
Regulation of cancer cell-cycle by statins
|
DUTTA, ANINDYA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$230,751
|
|
Urologic Diseases
|
NCI
|
7R01CA116337-03
|
|
"Molecular Signatures of Lethal and Indolent Prostate Cancer"
|
RUBIN, MARK
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$532,731
|
|
Urologic Diseases
|
NCI
|
5R01CA107164-04
|
|
Multicenter clinical trials for TSC & related disorders
|
DABORA, SANDRA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$181,066
|
|
Urologic Diseases
|
NCI
|
5R01CA083867-09
|
|
DE NOVO DNA METHYLATION IN BLADDER CANCER
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$295,584
|
|
Urologic Diseases
|
NCI
|
5R01CA105181-04
|
|
Natural History of HPV Infections in Men
|
KOUTSKY, LAURA
|
UNIVERSITY OF WASHINGTON
|
WA
|
$652,646
|
|
Urologic Diseases
|
NIDDK
|
5R01DK069655-04
|
|
Hormones and Female Urinary Incontinence
|
LUE, TOM
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$288,592
|
|
Urologic Diseases
|
NCI
|
1R01CA120921-01A2
|
|
Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases
|
WHANG, YOUNG
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$272,655
|
|
Urologic Diseases
|
NIDDK
|
1R01DK077195-01A1
|
|
Mechanotransduction in bladder smooth muscle
|
ADAM, ROSALYN
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$324,062
|
|
Urologic Diseases
|
NCI
|
1R21CA122878-01A2
|
|
Development of DNA-templated IR quantum dots
|
KELLEY, SHANA
|
UNIVERSITY OF TORONTO
|
CANADA
|
$129,600
|
|
Urologic Diseases
|
NIDDK
|
1R21DK077667-01A1
|
|
Autonomic nervous system and benign prostatic hyperplasia
|
ST SAUVER, JENNIFER
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$226,650
|
|
Urologic Diseases
|
NCI
|
5R01CA119168-03
|
|
Internet-Based Education for Prostate Cancer Screening
|
TAYLOR, KATHRYN
|
GEORGETOWN UNIVERSITY
|
DC
|
$363,858
|
|
Urologic Diseases
|
NCI
|
5R01CA113903-04
|
|
Communication and Chemoprevention of Prostate Cancer
|
MEHTA, PARMENDER
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$247,753
|
|
Urologic Diseases
|
NCI
|
5R01CA114281-04
|
|
Redox Effects of Selenium for Prostate Cancer Prevention
|
ZHONG, WEIXIONG
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$272,472
|
|
Urologic Diseases
|
NCI
|
5R01CA076639-11
|
|
IL-10 Regulation of Lymphangiogenesis in Prostate Cancer
|
STEARNS, MARK
|
DREXEL UNIVERSITY
|
PA
|
$320,012
|
|
Urologic Diseases
|
NIDDK
|
1R01DK078075-01A1
|
|
Mechanisms of regulation of LRH-1, Nanog and SF-1 by DAX-1
|
FLETTERICK, ROBERT
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$371,548
|
|
Urologic Diseases
|
NIDDK
|
1R01DK078172-01A1
|
|
Economic Analysis of the Urinary Incontinence Treatment Network Trials (E-UITN)
|
SUBAK, LESLEE
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$189,000
|
|
Urologic Diseases
|
NIAID
|
5R01AI072577-02
|
|
Molecular Epidemiology, Virulence, and Genomic Characterization of Ureaplasmas
|
WAITES, KEN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$400,252
|
|
Urologic Diseases
|
NCI
|
5R01CA112663-09
|
|
T-bet and Tumor Immunity
|
GLIMCHER, LAURIE
|
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
|
MA
|
$297,397
|
|
Urologic Diseases
|
NIA
|
2R01AG019241-06A2
|
|
Prevention of Alzheimer's Diseae by Vitamin E and Selenium
|
MARKESBERY, WILLIAM
|
UNIVERSITY OF KENTUCKY
|
KY
|
$1,304,793
|
|
Urologic Diseases
|
NIDDK
|
1R01DK077917-01A1
|
|
Neurotrophins and Neuropeptides in Colon and Bladder Hypersensitivity
|
QIAO, LIYA
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
VA
|
$298,000
|
|
Urologic Diseases
|
NCI
|
1R01CA122246-01A2
|
|
Pathogenetics of a Clinically-favorable Prostate Cancer Subtype
|
POLLACK, JONATHAN
|
STANFORD UNIVERSITY
|
CA
|
$206,190
|
|
Urologic Diseases
|
NCI
|
5R37CA028824-30
|
|
Synthesis of Antitumor Natural Products
|
DANISHEFSKY, SAMUEL
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$750,028
|
|
Urologic Diseases
|
NCI
|
5R01CA115618-03
|
|
Gender Differences in Bladder Cancer Risk Factors
|
LOFFREDO, CHRISTOPHER
|
GEORGETOWN UNIVERSITY
|
DC
|
$425,728
|
|
Urologic Diseases
|
NIEHS
|
1R01ES015584-01A1
|
|
Epigenetic Basis for Prostate Carcinogenesis following Early Estrogenic Exposures
|
PRINS, GAIL
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$504,593
|
|
Urologic Diseases
|
NCI
|
1R01CA122247-01A2
|
|
Targeting DHT Catabolism by AKR1Cs for Prostrate Cancer Prevention and Treatment.
|
STOLZ, ANDREW
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$304,403
|
|
Urologic Diseases
|
NCI
|
2R01CA095045-06
|
|
Vitamin D in Prostate Cancer: Tumor Vasculature Effects
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$270,000
|
|
Urologic Diseases
|
NIAID
|
2R01AI056021-24
|
|
The multiple antibiotic resistance (Mar) regulon
|
LEVY, STUART
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$611,653
|
|
Urologic Diseases
|
NIDDK
|
2R01DK067223-04
|
|
eNOS Regulatory Mechanisms in Penile Vascular Function
|
BURNETT, ARTHUR
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$348,500
|
|
Urologic Diseases
|
NCI
|
2U01CA098710-05
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
THUN, MICHAEL
|
AMERICAN CANCER SOCIETY, INC.
|
GA
|
$1,063,219
|
|
Urologic Diseases
|
NCI
|
2U01CA098216-05
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3
|
RIBOLI, ELIO
|
U OF L IMPERIAL COL OF SCI/TECHNLGY/MED
|
UK
|
$1,299,337
|
|
Urologic Diseases
|
NCI
|
1R01CA122558-01A2
|
|
Chemoprevention of urinary bladder carcinogenesis by flavokawain A
|
ZI, XIAOLIN
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$333,903
|
|
Urologic Diseases
|
NICHD
|
5R01HD042012-07
|
|
Function of PIWI/Argonuate Proteins in Spermatogenesis
|
LIN, HAIFAN
|
YALE UNIVERSITY
|
CT
|
$324,053
|
|
Urologic Diseases
|
NIEHS
|
5R01ES014460-03
|
|
Three-generation Human Study of Reproductive Effects of Marine Food Contaminants
|
GRANDJEAN, PHILIPPE
|
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
|
MA
|
$476,879
|
|
Urologic Diseases
|
NINDS
|
5R21NS052559-02
|
|
Neuroprotection selective Estrogen or Genistein in Spinal Cord Injury
|
FLOYD, CANDACE
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$158,594
|
|
Urologic Diseases
|
NCI
|
5R01CA113363-04
|
|
Prostate Cancer Prevention by Diallyl Trisulfide
|
SINGH, SHIVENDRA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$276,733
|
|
Urologic Diseases
|
NIA
|
5R01AG028048-02
|
|
Elastic Fiber Homeostasis in the Vaginal Wall
|
WORD, RUTH
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$315,413
|
|
Urologic Diseases
|
NCI
|
5R01CA118947-03
|
|
Chemopreventive Signaling Mechanisms in Prostate Cancer
|
KONG, AH-NG
|
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
|
NJ
|
$260,445
|
|
Urologic Diseases
|
NIDDK
|
5R01DK067386-04
|
|
Calcineurin in Congenital Urinary Tract Obstruction
|
CHEN, FENG
|
WASHINGTON UNIVERSITY
|
MO
|
$300,690
|
|
Urologic Diseases
|
NIDDK
|
5R01DK065992-05
|
|
Transgenic Mice- Recomb., Fate-Mapping,and Ca2+signaling
|
KOTLIKOFF, MICHAEL
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$358,466
|
|
Urologic Diseases
|
NIDDK
|
5R01DK069988-04
|
|
Nicotinic-Purinergic Modulation of Bladder Contraction
|
SOMOGYI, GEORGE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$285,735
|
|
Urologic Diseases
|
NIDDK
|
5R37DK049430-14
|
|
AFFERENT MECHANISMS UNDERLYING BLADDER PAIN
|
DEGROAT, WILLIAM
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$338,744
|
|
Urologic Diseases
|
NIDDK
|
1R01DK070618-01A2
|
|
Control of Dynamically Coupled Cavitation Bubbles in Shock Wave Lithotripsy
|
HAMILTON, MARK
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$333,896
|
|
Urologic Diseases
|
NCI
|
2R01CA097134-06A1
|
|
Repressors in Prostate Cancer
|
ROSENFELD, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$311,178
|
|
Urologic Diseases
|
NCI
|
1R01CA132317-01A2
|
|
Therapeutic Targeting of Wnt Signaling
|
WU, DIANQING
|
YALE UNIVERSITY
|
CT
|
$342,807
|
|
Urologic Diseases
|
NCI
|
5U10CA046368-21
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$315,196
|
|
Urologic Diseases
|
NCI
|
5U10CA038926-23
|
|
Southwest Oncology Group Statistical Center
|
CROWLEY, JOHN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$4,459,748
|
|
Urologic Diseases
|
NCI
|
5R01CA112505-03
|
|
Multiattribute decision theory for IMRT plan selection
|
PHILLIPS, MARK
|
UNIVERSITY OF WASHINGTON
|
WA
|
$241,983
|
|
Urologic Diseases
|
NIDDK
|
5R01DK075732-02
|
|
Pathogenesis of Candida glabrata in the Urinary Tract
|
CORMACK, BRENDAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$319,009
|
|
Urologic Diseases
|
NCI
|
5R01CA113553-03
|
|
Targeting the PEX Domain of MT1-MMP: Novel Cancer Therapy
|
CAO, JIAN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
NY
|
$267,147
|
|
Urologic Diseases
|
NCI
|
5U10CA010953-40
|
|
Radiologial Physics Center
|
IBBOTT, GEOFFREY
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$2,445,710
|
|
Urologic Diseases
|
NHLBI
|
2R01HL071138-05A1
|
|
In the Penis, RhoA Activation is Enhanced by Guanine Nucleotide Exchange Factors
|
WEBB, R.
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
GA
|
$367,500
|
|
Urologic Diseases
|
NIDDK
|
2K24DK062895-06
|
|
Osteoporosis in Older Men and Women
|
GREENSPAN, SUSAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$179,335
|
|
Urologic Diseases
|
NCI
|
1R21CA126622-01A1
|
|
A High-throughput Route to Synthetic Antibodies for Array-based Cancer Detection
|
CHAPUT, JOHN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$198,505
|
|
Urologic Diseases
|
NCI
|
1K07CA127214-01A1
|
|
Genetic Susceptibility to Cancers of the Prostate and Urinary Bladder
|
BEEBE-DIMMER, JENNIFER
|
WAYNE STATE UNIVERSITY
|
MI
|
$132,819
|
|
Urologic Diseases
|
NCI
|
5R01CA123063-02
|
|
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
|
LOKESHWAR, VINATA
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$260,623
|
|
Urologic Diseases
|
NCI
|
1R21CA127834-01A1
|
|
An Interactive Video Doctor to Encourage Cancer Screening
|
WALSH, JUDITH
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$167,706
|
|
Urologic Diseases
|
NIA
|
5R01AG028426-02
|
|
Longevity and Medical Treatment in Old Age
|
KAUFMAN, SHARON
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$461,783
|
|
Urologic Diseases
|
NIAID
|
5R01AI060706-05
|
|
Noninvasive diagnosis of BKV nephropathy
|
SUTHANTHIRAN, MANIKKAM
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$351,604
|
|
Urologic Diseases
|
NIAID
|
5R01AI068888-02
|
|
Role of LOS and Opa in gonococcal host interactions
|
STEIN, DANIEL
|
UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS
|
MD
|
$327,777
|
|
Urologic Diseases
|
NCI
|
1R21CA127784-01A1
|
|
"Strength training, Self-efficacy, and Function in Blacks with Prostate Cancer."
|
HURLEY, BERNARD
|
UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS
|
MD
|
$165,375
|
|
Urologic Diseases
|
NICHD
|
1R03HD055268-01A1
|
|
Regulation of insulins by the Rhox5 homeobox gene supports spermatogenesis
|
MACLEAN, JAMES
|
SOUTHERN ILLINOIS UNIVERSITY CARBONDALE
|
IL
|
$72,250
|
|
Urologic Diseases
|
NCI
|
1R21CA122570-01A2
|
|
Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
|
PANNELL, LEWIS
|
UNIVERSITY OF SOUTH ALABAMA
|
AL
|
$165,375
|
|
Urologic Diseases
|
NCI
|
1R01CA127300-01A1
|
|
New Mice Models for Studies of Androgen Receptor in Prostate Cancer
|
CHANG, CHAWNSHANG
|
UNIVERSITY OF ROCHESTER
|
NY
|
$319,550
|
|
Urologic Diseases
|
NIDDK
|
5R01DK058859-08
|
|
Natural History of Prostatism: The Olmsted County Study
|
ST. SAUVER, JENNIFER
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$548,077
|
|
Urologic Diseases
|
NCI
|
5R01CA087869-08
|
|
Epigenetics, Stem Cells, and Cancer
|
JAENISCH, RUDOLF
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
MA
|
$863,846
|
|
Urologic Diseases
|
NIDDK
|
5R21DK076000-02
|
|
The Role of Bone Morphogenetic Protein-7 in Renal Endothelial Cell Biology
|
MORRISSEY, JEREMIAH
|
WASHINGTON UNIVERSITY
|
MO
|
$186,200
|
|
Urologic Diseases
|
NCI
|
5R01CA118962-02
|
|
Prevention of Prostate Cancer Progression Using Omega-3 Fatty Acids
|
DE GRAFFENRIED, LINDA
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$249,660
|
|
Urologic Diseases
|
NIDDK
|
5R01DK062284-06
|
|
Dietary Oxalate and Kidney Stone Formation
|
ASSIMOS, DEAN
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$297,332
|
|
Urologic Diseases
|
NCI
|
1R21CA127768-01A1
|
|
Long-term prediction of prostate cancer death from kallikreins measured in blood
|
LILJA, HANS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$309,537
|
|
Urologic Diseases
|
NCI
|
5U01CA086402-09
|
|
San Antonio Center - Biomarkers for Prostate Cancer
|
THOMPSON, IAN
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$905,861
|
|
Urologic Diseases
|
NCI
|
1U01CA127615-01A1
|
|
Genome-Wide Association Analysis of Bladder Cancer
|
WU, XIFENG
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$1,077,416
|
|
Urologic Diseases
|
NCI
|
1R01CA127735-01A1
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
MI
|
$312,288
|
|
Urologic Diseases
|
NCI
|
2R01CA069158-12A1
|
|
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS
|
GUISE, THERESA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$276,088
|
|
Urologic Diseases
|
NIA
|
5R01AG027017-03
|
|
Longitudinal Impact of CNS Polypharmacy on Geriatric Sy*
|
HANLON, JOSEPH
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$173,813
|
|
Urologic Diseases
|
NCI
|
5R01CA029997-21
|
|
Role of Eicosanoids in Tumor Cell Metastasis
|
HONN, KENNETH
|
WAYNE STATE UNIVERSITY
|
MI
|
$322,146
|
|
Urologic Diseases
|
NCI
|
5R01CA121459-03
|
|
Role of ATBF1 inactivation in the development and progression of prostate cancer
|
DONG, JIN-TANG
|
EMORY UNIVERSITY
|
GA
|
$263,700
|
|
Urologic Diseases
|
NIDDK
|
5R37DK054824-09
|
|
Nitric Oxide in Bladder Neural-Epithelial Signaling
|
BIRDER, LORI
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$273,735
|
|
Urologic Diseases
|
NIDDK
|
5R01DK048215-11
|
|
Molecular Analysis of Collagen in Non-compliant Bladders
|
HOWARD, PAMELA
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$316,418
|
|
Urologic Diseases
|
NIDDK
|
5R01DK071875-03
|
|
Heme Oxygenase-1 Gene Expression by TGF-Beta 1
|
AGARWAL, ANUPAM
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$207,682
|
|
Urologic Diseases
|
NIAID
|
5R01AI064749-04
|
|
Interaction of Chalmydia with Innate Immune Receptors
|
INGALLS, ROBIN
|
BOSTON MEDICAL CENTER
|
MA
|
$299,513
|
|
Urologic Diseases
|
NCRR
|
1S10RR024727-01
|
|
Xenogen Rodent Imaging System
|
NAPOLI, JOSEPH
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$379,374
|
|
Urologic Diseases
|
NIAID
|
5R01AI040915-10
|
|
CHLAMYDIA TRACHOMATIS ENVELOPE COMPONENTS AND VIRULENCE
|
RAULSTON, JANE
|
EAST TENNESSEE STATE UNIVERSITY
|
TN
|
$339,510
|
|
Urologic Diseases
|
NCI
|
1R21CA127696-01A1
|
|
The p270 SWI/SNF subunit as a potential Wilms' tumor susceptibility gene
|
MORAN, ELIZABETH
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
NJ
|
$175,500
|
|
Urologic Diseases
|
NCCAM
|
5R01AT002890-02
|
|
Novel Herbal Medicine for the Treatment of Prostate Cancer
|
DAMODARAN, CHENDIL
|
UNIVERSITY OF KENTUCKY
|
KY
|
$355,097
|
|
Urologic Diseases
|
NIAID
|
5K08AI057737-05
|
|
Type 1 fimbrial variation in E coil 018 k1 h7 virulence
|
WEISSMAN, SCOTT
|
CHILDREN'S HOSPITAL AND REG MEDICAL CTR
|
WA
|
$120,420
|
|
Urologic Diseases
|
NIDDK
|
5R01DK065837-04
|
|
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN
|
GUISE, THERESA
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$333,010
|
|
Urologic Diseases
|
NIDDK
|
5R01DK063300-04
|
|
Systematic Reviews in Urologic Diseases
|
WILT, TIMOTHY
|
MINNESOTA VETERANS RESEARCH INST
|
MN
|
$231,426
|
|
Urologic Diseases
|
NIDDK
|
5R01DK067133-05
|
|
Risk for Renal Injury Caused by Shock Wave Lithotripsy
|
EVAN, ANDREW
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$328,641
|
|
Urologic Diseases
|
NIAID
|
5R37AI032725-15
|
|
Immunology of Infection with Neisseria gonorrhoeae
|
RICE, PETER
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$549,530
|
|
Urologic Diseases
|
NIGMS
|
5R01GM077482-02
|
|
Mechanisms Underlying Drug-Diet Interactions
|
PAINE, MARY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$312,667
|
|
Urologic Diseases
|
NCI
|
5U01CA086323-09
|
|
Development/Clinical Validation Markers for Prostate Ca
|
PARTIN, ALAN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$702,609
|
|
Urologic Diseases
|
NCI
|
1R21CA128352-01A1
|
|
A phase II study of IPI-504 in metastatic hormone refractory prostate cancer
|
OH, WILLIAM
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$268,452
|
|
Urologic Diseases
|
NCI
|
5R01CA111782-04
|
|
Translating Prostate Cancer Gene Expression Subtypes
|
BROOKS, JAMES
|
STANFORD UNIVERSITY
|
CA
|
$262,921
|
|
Urologic Diseases
|
NCI
|
7R01CA115985-04
|
|
Molecular analysis of metastatic prostate cancer in mice
|
SHEN, MICHAEL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$301,498
|
|
Urologic Diseases
|
NICHD
|
5R01HD053900-02
|
|
Environmental cues regulating primordial geerm cell development
|
MOLYNEAUX, KATHLEEN
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$302,820
|
|
Urologic Diseases
|
NCI
|
5R01CA065237-20
|
|
Ternary Complex that Drives T Cell Activation
|
FATHMAN, C
|
STANFORD UNIVERSITY
|
CA
|
$275,622
|
|
Urologic Diseases
|
NIDDK
|
5R01DK054257-10
|
|
Molecular Complementation of Nuclear Receptors
|
KOH, JOHN
|
UNIVERSITY OF DELAWARE
|
DE
|
$265,106
|
|
Urologic Diseases
|
NCI
|
5R01CA059897-15
|
|
METABOLIC IMAGING OF THE PROSTATE USING 3-D MRSI
|
VIGNERON, DANIEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$415,964
|
|
Urologic Diseases
|
NCI
|
5R01CA113996-03
|
|
Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion
|
GIANCOTTI, FILIPPO
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$383,595
|
|
Urologic Diseases
|
NCI
|
5R21CA124511-02
|
|
Effect of Dietary Omega-3 Fatty Acid Supplement on Prostate Cancer Metastasis
|
CHEN, YONG
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$177,600
|
|
Urologic Diseases
|
NCI
|
5R01CA101035-05
|
|
TARGETS OF AMINO ACID RESTRICTION IN PROSTATE CANCER
|
MEADOWS, GARY
|
WASHINGTON STATE UNIVERSITY
|
WA
|
$256,811
|
|
Urologic Diseases
|
NCI
|
5R01CA107668-05
|
|
Fish Oil Supplement Prevention of Prostate Cancer
|
CHEN, YONG
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
NC
|
$278,932
|
|
Urologic Diseases
|
NCI
|
5R01CA113392-04
|
|
Bone matrix proteins in prostate cancer progression
|
ROY-BURMAN, PRADIP
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$305,244
|
|
Urologic Diseases
|
NIAID
|
5R37AI029549-18
|
|
CHAPERONE ASSISTED PILI ASSEMBLY IN PATHOGENIC E COLI
|
HULTGREN, SCOTT
|
WASHINGTON UNIVERSITY
|
MO
|
$355,788
|
|
Urologic Diseases
|
NCI
|
5R03CA128086-02
|
|
Epitope Array to Complement PSA Tests for Early Detection of Prostate Cancer
|
ZENG, GANG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$77,250
|
|
Urologic Diseases
|
NCI
|
5R01CA067044-10
|
|
Genetic Epidemiology of Prostate Cancer
|
WHITTEMORE, ALICE
|
STANFORD UNIVERSITY
|
CA
|
$385,278
|
|
Urologic Diseases
|
NCI
|
5R01CA079903-09
|
|
Zinc Transport Relationships in Prostate Cancer Cells
|
FRANKLIN, RENTY
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$253,449
|
|
Urologic Diseases
|
NCI
|
5R01CA118124-02
|
|
Analysis of Homing Receptors in Prostate Cancer
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$282,720
|
|
Urologic Diseases
|
NCI
|
1R21CA121586-01A2
|
|
MRI Guided and Tumor Targeted HDR Brachytherapy for Recurrent Prostate Cancer
|
MENARD, CYNTHIA
|
UNIVERSITY HEALTH NETWORK
|
CANADA
|
$123,408
|
|
Urologic Diseases
|
NCI
|
1R43CA132538-01
|
|
Dynamic, Structure Driven Fragment Based Design of Selective Androgen Modulators
|
HAGLER, ARNOLD
|
SHIFA BIOMEDICAL
|
PA
|
$284,480
|
|
Urologic Diseases
|
NCI
|
5R01CA106835-04
|
|
Hypofractionated IMRT for Localized Prostate Cancer
|
RITTER, MARK
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$221,342
|
|
